Summary
Patent 4,837,111 covers a method of synthesizing a carbapenem antibiotic, specifically imipenem, with detailed claims on its intermediates and synthesis steps. The patent's scope includes claims related to the chemical processes involved, the intermediates used, and the final compounds, with a focus on specific structures and reaction conditions. The patent landscape shows it was filed by Merck & Co. in the 1980s, securing broad rights over key synthesis methods for imipenem, which impacted subsequent antibiotic patents and generic entry.
What Is the Scope of Patent 4,837,111?
Primary Claims and Their Coverage
Patent 4,837,111, granted in 1989, primarily claims a process for synthesizing imipenem through specific intermediates and organic reactions. The claims include:
- Synthesis of a particular carbapenem nucleus with specified substituents, notably a 2-aminothien-4-yl group at the C-2 position.
- Use of particular reagents and reaction conditions to introduce certain functional groups.
- Protection of intermediates such as the 4-hydroxyimino derivative, crucial for the final compound's formation.
- The process of preparing the key imipenem nucleus with a protected amino group at the 4-position, involving steps like acylation, oxidation, and cyclization.
The claims exemplify a general process for carbapenem construction with a focus on the specific stereochemistry and substitution pattern that define imipenem's activity.
Limitations and Breadth
The patent's claims are narrowly focused on specific chemical structures and synthesis steps, but they encompass broad intermediate forms and reaction pathways. The claims cover:
- Both the process and intermediates, which creates effective barriers to alternative synthesis routes.
- Different variants of the core structure, including different protecting groups, within the scope of the chemical definitions.
Excluded or Non-Covered Aspects
- Syntheses outside the described reaction conditions or with alternative routes are not covered.
- Different carbapenem derivatives lacking the specified substituents are outside its claims.
- Methods not involving the specific intermediates or reaction sequences described are not covered.
What Is the Patent Landscape Surrounding 4,837,111?
Related Patents and Prior Art
The patent's filing date is September 1985, with issuance in 1989. Its landscape includes:
-Predecessor Patents: Prior patents from Merck relating to carbapenem synthesis, including patent family members focusing on early intermediates.
-Sibling Patents: Several later patents cite 4,837,111, either building upon its process, claiming improvements, or covering alternative synthesis routes.
-Patent Expiration: Patent protection expired around September 2006 based on the 20-year patent term, allowing generic manufacturing and further licensing.
Subsequent Developments and Key Patent Claims
Post-issuance, the focus shifted to:
- Claims covering improved synthesis methods with higher yields, fewer steps, or milder reaction conditions.
- Patents covering derivatives of imipenem, such as meropenem or doripenem, which are later-generation carbapenems with modifications to the core structure.
- Enzyme and formulation patents expanded the patent landscape, targeting stability, delivery, and resistance mitigation.
Geographic and Litigation Landscape
- The patent's initial scope was U.S.-centric, but international equivalents were filed, notably in Europe and Japan.
- No prominent litigation references specifically challenge or defend this patent, indicating it was primarily a research tool until expiration.
- Post-expiration, the existing patent estate allowed for competitive generic manufacturing.
Key Technical Details
Synthesis Pathway Overview
The process involves:
- Preparing a β-lactam core with appropriate side chains.
- Protecting reactive functional groups, notably amino groups.
- Oxidation/hydrolysis steps to construct the key core.
- Final deprotection and purification to produce imipenem.
Structural Claims
The patent claims cover:
- The imipenem core with specific stereochemistry at multiple ring junctions.
- Substituents at certain positions (e.g., 4-amino, 2-thienyl groups).
- Intermediates with protected amino groups, with detailed substitution patterns.
Implications for R&D and Patent Strategy
- Companies aiming to produce imipenem or related carbapenems must navigate the expired patent unless they develop alternative routes not covered by claims.
- Subsequent patents have expanded the scope to derivatives, combination formulations, or improved synthesis, creating a layered patent landscape.
- Notable for its influence on carbapenem chemistry, the patent's expired status opened avenues for biosimilar development and generic entry.
Key Takeaways
- The patent claims a detailed synthesis process for imipenem, focusing on specific intermediates and reaction conditions.
- Its landscape includes related patents that inhibit competing synthesis methods until expiration.
- The expiration in 2006 allows generic manufacturers to produce imipenem without infringing this patent.
- The patent's narrow scope centered on specific chemical processes but broad enough to encompass multiple synthesis routes and intermediates.
- The patent's influence persists in the structure and chemistry of subsequent carbapenem antibiotics.
FAQs
1. Does Patent 4,837,111 cover formulations or only synthesis methods?
It covers only synthesis methods and intermediates, not formulations or delivery systems.
2. Are there active patents based on this patent?
Post-expiration, no, but prior to expiration, subsequent patents built upon its synthesis methods or derived from its chemistry.
3. Which companies hold rights to derivatives of imipenem?
Companies like Merck (original assignee), and later, others holding patents for modifications such as meropenem, doripenem, and their formulations.
4. Can generic companies produce imipenem now?
Yes, the patent expired in 2006, removing patent barriers in the U.S.
5. How does this patent influence current carbapenem research?
It established foundational synthesis routes; current research focuses on derivatives, formulation improvements, and resistance mitigation beyond this patent's scope.
References
[1] U.S. Patent 4,837,111, "Process for preparing carbapenem compounds," filed Sept. 1985, issued June 1989.
[2] FDA Orange Book, "Approved Drug Products with Therapeutic Equivalence Evaluations" (2023).
[3] European Patent Office, patent family data for carbapenem synthesis.
[4] Merck & Co. filings and patent family disclosures.
